KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.96

Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide.

Andrew J Armstrong, Arun A Azad, Taro Iguchi, Arnulf Stenzl, Nicolas Mottet, David Russell, Matt Rosales, Gabriel P Haas, Fred Saad, Maha Hussain, Cora N Sternberg

J Clin Oncol 44(14) 1309-1322

PMID41894648
PMCIDPMC13166072
DOI10.1200/JCO-24-02829
发表日期2026-03-27
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

PURPOSE: In patients who received enzalutamide, we characterized the development of radiographic progression (rPD) without prostate-specific antigen (PSA) rise or progression in metastatic hormone-sensitive prostate cancer (mHSPC) and nonmetastatic castration-resistant prostate cancer (nmCRPC). METHODS: We conducted a post hoc analysis in two phase III trials (N = 2,551; ARCHES [ClinicalTrials.gov identifier: NCT02677896]; PROSPER [ClinicalTrials.gov identifier: NCT02003924]) for co-occurrence of rPD ± Prostate Cancer Working Group 2/3-defined PSA progression, and rPD ± any PSA rise from baseline/nadir by treatment. Kaplan-Meier methods were used for overall survival (OS) outcomes. RESULTS: In ARCHES, 3.5% and 8.5% of 574 patients with mHSPC treated with enzalutamide plus androgen-deprivation therapy (ADT) had no PSA rise or PSA progression at rPD, respectively. Of 79 patients with rPD who received enzalutamide plus ADT, 25.3% had no PSA rise and 62.0% did not meet PSA progression criteria compared with 7.4% and 38.3% of 188 patients with rPD treated with ADT alone, respectively. In PROSPER, 4.4% and 10.3% of 933 patients with nmCRPC treated with enzalutamide plus ADT had no PSA rise or PSA progression, respectively, at rPD. However, of 187 patients with rPD who received enzalutamide plus ADT, 21.9% had no PSA rise and 51.3% did not meet PSA progression criteria compared with 3.6% and 18.8% of 224 patients treated with placebo/ADT, respectively. Liver metastases were >5-fold higher in enzalutamide-treated patients with rPD events versus control, although sample size was small. Compared with no rPD, enzalutamide-treated patients with rPD ± PSA rise or progression had worse OS. CONCLUSION: Given the frequent discordance and poor prognosis of imaging-based progression in the absence of PSA changes during enzalutamide treatment in mHSPC and nmCRPC, periodic surveillance using imaging is recommended.

KM 提取结果

2 个 Figure · 4 个 KM 面板

进入结果中心
KM Figure2 个面板

FIG 3.

FIG 3. ARCHES: Kaplan-Meier curves of OS by rPD with and without any PSA rise in patients treated with (A) enzalutamide plus ADT or (B) placebo plus ADT (ITT population). OS is defined as the time from random assignment to death of any cause. rPD was defined by RECIST v1.1 for soft tissue disease or the appearance of ≥2 new lesions on bone scan. The data cutoff for ARCHES was May 28, 2021. ADT, androgen-deprivation therapy; HR, hazard ratio; ITT, intention-to-treat; NE, not estimable; OS, overall survival; PSA, prostate-specific antigen; rPD, radiographic progression. a No rPD is the reference. b From the log-rank test.

A

overall survival

FIG 3. · Panel A

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel A 是同一 FIG 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

overall survival

FIG 3. · Panel B

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel B 是同一 FIG 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure2 个面板

FIG 4.

FIG 4. PROSPER: Kaplan-Meier curves of OS by rPD with and without any PSA rise in patients treated with (A) enzalutamide or (B) placebo (ITT population). OS is defined as the time from random assignment to death due to any cause. rPD was defined by RECIST v1.1 for soft tissue disease or the appearance of ≥1 new lesions on bone scan. The data cutoff for PROSPER was June 28, 2017. a No rPD is the reference. b From the log-rank test. ADT, androgen-deprivation therapy; HR, hazard ratio; ITT, intention-to-treat; NE, not estimable; OS, overall survival; PSA, prostate-specific antigen; rPD, radiographic progression.

A

overall survival

FIG 4. · Panel A

quality_warning 待 EXE 对齐 预期 3 条 已提取 1 条

Panel A 是同一 FIG 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 3 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
B

overall survival

FIG 4. · Panel B

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel B 是同一 FIG 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme upward reversal曲线 3:extreme upward reversal
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.FIG 1. rPD with and without any rise in PSA in (A) ARCHES and (B) PROSPER (ITT population). PSA values were closest to the rPD date, including 90 days after rPD. The data cutoff for ARCHES was October 14, 2018; the data cutoff for PROSPER was June 28, 2017. ADT, androgen-deprivation therapy; ITT, intention-to-treat; PSA, prostate-specific antigen; rPD, radiographic progression.
非 KM Figure
FIG 2.FIG 2. rPD in the absence of PCWG 2/3-defined PSA progression and any rise in PSA in (A) ARCHES and (B) PROSPER (ITT population). PSA values were closest to the rPD date including 90 days after rPD. The data cutoff for ARCHES was October 14, 2018; the data cutoff for PROSPER was June 28, 2017. ADT, androgen-deprivation therapy; ITT, intention-to-treat; PCWG, Prostate Cancer Working Group; PSA, prostate-specific antigen; rPD, radiographic progression.
非 KM Figure